466 related articles for article (PubMed ID: 10025740)
1. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile.
Amagai M; Tsunoda K; Zillikens D; Nagai T; Nishikawa T
J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):167-70. PubMed ID: 10025740
[TBL] [Abstract][Full Text] [Related]
2. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris.
Mahoney MG; Wang Z; Rothenberger K; Koch PJ; Amagai M; Stanley JR
J Clin Invest; 1999 Feb; 103(4):461-8. PubMed ID: 10021453
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus.
Amagai M; Komai A; Hashimoto T; Shirakata Y; Hashimoto K; Yamada T; Kitajima Y; Ohya K; Iwanami H; Nishikawa T
Br J Dermatol; 1999 Feb; 140(2):351-7. PubMed ID: 10233237
[TBL] [Abstract][Full Text] [Related]
4. The transition of pemphigus vulgaris into pemphigus foliaceus: a reflection of changing desmoglein 1 and 3 autoantibody levels in pemphigus vulgaris.
Harman KE; Gratian MJ; Shirlaw PJ; Bhogal BS; Challacombe SJ; Black MM
Br J Dermatol; 2002 Apr; 146(4):684-7. PubMed ID: 11966706
[TBL] [Abstract][Full Text] [Related]
5. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay.
Komai A; Amagai M; Ishii K; Nishikawa T; Chorzelski T; Matsuo I; Hashimoto T
Br J Dermatol; 2001 Jun; 144(6):1177-82. PubMed ID: 11422038
[TBL] [Abstract][Full Text] [Related]
6. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype.
Harman KE; Gratian MJ; Bhogal BS; Challacombe SJ; Black MM
Br J Dermatol; 2000 Aug; 143(2):343-8. PubMed ID: 10951143
[TBL] [Abstract][Full Text] [Related]
7. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
[TBL] [Abstract][Full Text] [Related]
8. [Detection of serum desmoglein antibody level using enzyme-linked immunosorbent assay (ELISA) for monitoring disease activity in patients with pemphigus vulgaris].
Zhong S; Qiu YF; Han BB; Zhao JY; Zhu XJ; Chen XX
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 43(3):414-5. PubMed ID: 21681274
[TBL] [Abstract][Full Text] [Related]
9. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus.
Ohyama M; Amagai M; Hashimoto T; Nousari HC; Anhalt GJ; Nishikawa T
J Am Acad Dermatol; 2001 Apr; 44(4):593-8. PubMed ID: 11260531
[TBL] [Abstract][Full Text] [Related]
10. Anti-Desmoglein 1 and 3 Autoantibody Levels in Endemic Pemphigus Foliaceus and Pemphigus Vulgaris from Brazil.
Oliveira LA; Marquart-Filho A; Trevilato G; Timoteo RP; Mukai M; Roselino AM; Petzl-Erler ML
Clin Lab; 2016 Jul; 62(7):1209-1216. PubMed ID: 28164651
[TBL] [Abstract][Full Text] [Related]
11. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels.
Harman KE; Seed PT; Gratian MJ; Bhogal BS; Challacombe SJ; Black MM
Br J Dermatol; 2001 Apr; 144(4):775-80. PubMed ID: 11298536
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin autoantibody profile in patients with pemphigus vulgaris.
Oliveira ME; Culton DA; Prisayanh P; Qaqish BF; Diaz LA
Br J Dermatol; 2013 Oct; 169(4):812-8. PubMed ID: 23725016
[TBL] [Abstract][Full Text] [Related]
13. Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay.
Ishii K; Amagai M; Ohata Y; Shimizu H; Hashimoto T; Ohya K; Nishikawa T
J Am Acad Dermatol; 2000 May; 42(5 Pt 2):859-61. PubMed ID: 10767686
[TBL] [Abstract][Full Text] [Related]
14. The use of BIOCHIP technique in diagnosis of different types of pemphigus: Vulgaris and foliaceus.
Adaszewska A; Kalinska-Bienias A; Jagielski P; Wozniak K; Kowalewski C
J Immunol Methods; 2019 May; 468():35-39. PubMed ID: 30910537
[TBL] [Abstract][Full Text] [Related]
15. T lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1.
Lin MS; Swartz SJ; Lopez A; Ding X; Fairley JA; Diaz LA
J Invest Dermatol; 1997 Dec; 109(6):734-7. PubMed ID: 9406813
[TBL] [Abstract][Full Text] [Related]
16. A comparison of anti-desmoglein antibodies and indirect immunofluorescence in the serodiagnosis of pemphigus vulgaris.
Zagorodniuk I; Weltfriend S; Shtruminger L; Sprecher E; Kogan O; Pollack S; Bergman R
Int J Dermatol; 2005 Jul; 44(7):541-4. PubMed ID: 15985020
[TBL] [Abstract][Full Text] [Related]
17. Role of Dsg1- and Dsg3-Mediated Signaling in Pemphigus Autoantibody-Induced Loss of Keratinocyte Cohesion.
Walter E; Vielmuth F; Wanuske MT; Seifert M; Pollmann R; Eming R; Waschke J
Front Immunol; 2019; 10():1128. PubMed ID: 31178865
[TBL] [Abstract][Full Text] [Related]
18. Serum and salivary desmoglein 1 and 3 enzyme-linked immunosorbent assay in pemphigus vulgaris: correlation with phenotype and severity.
Hallaji Z; Mortazavi H; Lajevardi V; Tamizifar B; AmirZargar A; Daneshpazhooh M; Chams-Davatchi C
J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):275-80. PubMed ID: 19709345
[TBL] [Abstract][Full Text] [Related]
19. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3.
Cheng SW; Kobayashi M; Kinoshita-Kuroda K; Tanikawa A; Amagai M; Nishikawa T
Br J Dermatol; 2002 Aug; 147(2):261-5. PubMed ID: 12174096
[TBL] [Abstract][Full Text] [Related]
20. Autoimmunity against desmosomal cadherins in pemphigus.
Amagai M
J Dermatol Sci; 1999 Jun; 20(2):92-102. PubMed ID: 10379702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
